Literature DB >> 27027098

VZV in biopsy-positive and -negative giant cell arteritis: Analysis of 100+ temporal arteries.

Don Gilden1, Teresa White1, Nelly Khmeleva1, Philip J Boyer1, Maria A Nagel1.   

Abstract

Entities:  

Year:  2016        PMID: 27027098      PMCID: PMC4794807          DOI: 10.1212/NXI.0000000000000216

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
We report the cumulative frequency, including previous studies,[1,2] showing varicella-zoster virus (VZV) antigen in 73/104 (70%) giant cell arteritis (GCA)–positive temporal arteries (TAs), in 58/100 (58%) GCA-negative TAs (patients who manifest clinical and laboratory features of GCA whose TA biopsies are pathologically negative for GCA) and in 11/61 (18%) normal TAs acquired at autopsy. The location of VZV antigen in specific arterial layers and pathologic findings in GCA-negative arteries helps to explain disease pathogenesis.

Methods.

De-identified formalin-fixed, paraffin-embedded TA biopsies were obtained from participants >50 years of age. Of 204 TAs, 104 were GCA-positive and 100 were GCA-negative. Age and sex were available for 96 GCA-positive TAs, 36 (37%) of which were in men and 60 (63%) in women, age 51–89 years. Of 100 GCA-negative TAs, age and sex data were available for 95 TAs, 40 (42%) of which were in men and 55 (58%) in women, age 50–89 years. Sixty-one control TAs were removed postmortem from age-matched participants. All TAs were examined immunohistochemically as described.[1] Location of viral antigen in adventitia, media, or intima was documented. VZV antigen-positive sections from 58 GCA-positive TAs, 58 GCA-negative TAs, and 11 normal TAs were analyzed for VZV DNA as described.[1] Sections 5 μm adjacent to those containing VZV antigen were stained with hematoxylin & eosin. If a GCA-negative TA section appeared to contain inflammatory cells, it was destained and immunostained with rabbit anti-CD45 as described.[2]

Results.

Immunohistochemical analysis revealed VZV antigen in 73/104 (70%) GCA-positive and 58/100 (58%) GCA-negative TAs compared to 11/61 (18%) normal TAs. VZV antigen was 3.89-fold more likely to be present in GCA-positive TAs than in normal TAs (95% confidence interval [CI] 2.3819, 7.2384, p < 0.0001) and 3.22 times more likely to be present in GCA-negative TAs than in normal TAs (95% CI 1.9391, 6.0303, p < 0.0001). All TAs contained viral antigen in multiple arterial layers (figure, A–F). In GCA-positive and GCA-negative TAs, viral antigen was seen in the adventitia (86% and 95%, respectively), media (67% and 53%, respectively), and intima (52% and 45%, respectively); in normal TAs, viral antigen was seen in the adventitia (91%) and equally in media (82%) and intima (82%).
Figure

Varicella-zoster virus (VZV) antigen in giant cell arteritis (GCA)–positive and GCA-negative temporal arteries (TAs) and inflammation adjacent to VZV antigen in GCA-negative TAs

VZV antigen in TAs of GCA-positive and GCA-negative patients (clinical and laboratory features of GCA whose TA biopsies were pathologically negative for GCA) was detected immunohistochemically using mouse anti-VZV gE immunoglobulin (Ig) G1 antibody (Santa Cruz Biotechnology, Dallas, TX; catalog no. SC-56995). After immunostaining with primary and biotinylated secondary antibodies, slides were treated with prediluted streptavidin-alkaline phosphatase (BD Biosciences, San Diego, CA) for 1 hour. The color reaction was developed under a light microscope using the fresh fuchsin substrate system (Dako, Carpinteria, CA) with levamisole (Dako; 24 μg/mL). VZV antigen is shown in the adventitia of a positive control VZV-infected cadaveric cerebral artery 14 days after infection in vitro (A), in the adventitia and media of a GCA-positive TA (B), and in the media and intima of a GCA-negative TA (C). No staining was seen when mouse isotype IgG1 was substituted for primary mouse anti-VZV gE IgG1 antibody (D–F). In GCA-negative TAs, hematoxylin & eosin (H&E) staining of TA sections adjacent to those containing VZV antigen revealed inflammatory cells (G, J, arrows) identified as CD45-positive (H, K, pink) after destaining H&E sections and immunostaining with rabbit anti-CD45 antibody (Abcam, Cambridge, MA; catalog no. AB10558). No staining was seen when normal rabbit serum was substituted for rabbit anti-CD45 antibody (I, L). 600× magnification.

Varicella-zoster virus (VZV) antigen in giant cell arteritis (GCA)–positive and GCA-negative temporal arteries (TAs) and inflammation adjacent to VZV antigen in GCA-negative TAs

VZV antigen in TAs of GCA-positive and GCA-negative patients (clinical and laboratory features of GCA whose TA biopsies were pathologically negative for GCA) was detected immunohistochemically using mouse anti-VZV gE immunoglobulin (Ig) G1 antibody (Santa Cruz Biotechnology, Dallas, TX; catalog no. SC-56995). After immunostaining with primary and biotinylated secondary antibodies, slides were treated with prediluted streptavidin-alkaline phosphatase (BD Biosciences, San Diego, CA) for 1 hour. The color reaction was developed under a light microscope using the fresh fuchsin substrate system (Dako, Carpinteria, CA) with levamisole (Dako; 24 μg/mL). VZV antigen is shown in the adventitia of a positive control VZV-infected cadaveric cerebral artery 14 days after infection in vitro (A), in the adventitia and media of a GCA-positive TA (B), and in the media and intima of a GCA-negative TA (C). No staining was seen when mouse isotype IgG1 was substituted for primary mouse anti-VZV gE IgG1 antibody (D–F). In GCA-negative TAs, hematoxylin & eosin (H&E) staining of TA sections adjacent to those containing VZV antigen revealed inflammatory cells (G, J, arrows) identified as CD45-positive (H, K, pink) after destaining H&E sections and immunostaining with rabbit anti-CD45 antibody (Abcam, Cambridge, MA; catalog no. AB10558). No staining was seen when normal rabbit serum was substituted for rabbit anti-CD45 antibody (I, L). 600× magnification. Of 58 GCA-positive, VZV antigen–positive TAs examined, all contained cellular DNA and 23 (40%) contained VZV DNA. Of 58 GCA-negative, VZV antigen–positive TAs examined, 51 contained cellular DNA, 9 (18%) of which contained VZV DNA. Nine of 11 normal VZV antigen-positive TAs contained cellular DNA, of which 3 (33%) contained VZV DNA. Adventitial inflammation was seen adjacent to viral antigen in 26 (52%) of 58 GCA-negative participants whose TAs contained VZV antigen (figure, G–L). No inflammation was seen in normal TAs containing VZV antigen.

Discussion.

Detection of VZV in 73/104 GCA-positive TAs (70%) and 58/100 GCA-negative TAs (58%) compared to 11/61 normal TAs (18%) was highly statistically significant (p < 0.0001). Despite formalin fixation, VZV DNA was detected by PCR in many VZV antigen–positive sections. Detection of VZV antigen without inflammation in normal TAs indicates that VZV reactivates subclinically in some people over age 50 years. The greater frequency of VZV in the adventitia than in media and intima in all groups most likely reflects transaxonal transport of virus along afferent nerve fibers that innervate the TA after reactivation from ganglia. VZV antigen and inflammation was usually patchy and detected in only some, but not all sections. Our exhaustive, research-focused evaluation is not practical for routine diagnostic work-up of TA biopsies. Immunohistochemical evaluation is worthwhile, but a negative result should cite possible shortfalls: specifically, a negative biopsy does not rule out GCA or VZV reactivation. Detection of adventitial inflammation adjacent to VZV antigen in 52% of GCA-negative TAs for the first time connects the presence of VZV with pathology in GCA-negative TAs. Inflammation restricted to the adventitia may represent a milder form of GCA[3] and has also been associated with ischemic optic neuropathy (ION).[4,5] Interestingly, we initially detected VZV in a TA from a patient with ION whose biopsy revealed both adventitial and intimal inflammation but not classic GCA.[6] Overall, finding VZV mostly in the adventitia of GCA-positive TAs and VZV with inflammation in the adventitia of GCA-negative TAs indicates that inflammation follows VZV reactivation from ganglia and transaxonal transport to arterial adventitia. The tempo and evolution of GCA (transmural inflammation and necrosis with giant or epithelioid cells) after virus infection of the adventitia and adventitial inflammation remains to be determined.
  6 in total

1.  Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis.

Authors:  Gabriel S Breuer; Ronit Nesher; Konstantin Reinus; Gideon Nesher
Journal:  Isr Med Assoc J       Date:  2013-06       Impact factor: 0.892

2.  Temporal artery biopsy for giant cell arteritis.

Authors:  Regina Taylor-Gjevre; Minh Vo; Dino Shukla; Lothar Resch
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

3.  Varicella zoster virus ischemic optic neuropathy and subclinical temporal artery involvement.

Authors:  Richard Salazar; Andrew N Russman; Maria A Nagel; Randall J Cohrs; Ravi Mahalingam; D Scott Schmid; Bette K Kleinschmidt-DeMasters; Eve M VanEgmond; Don Gilden
Journal:  Arch Neurol       Date:  2011-04

4.  Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.

Authors:  Don Gilden; Teresa White; Nelly Khmeleva; Anna Heintzman; Alexander Choe; Philip J Boyer; Charles Grose; John E Carpenter; April Rempel; Nathan Bos; Balasubramaniyam Kandasamy; Kelly Lear-Kaul; Dawn B Holmes; Jeffrey L Bennett; Randall J Cohrs; Ravi Mahalingam; Naresh Mandava; Charles G Eberhart; Brian Bockelman; Robert J Poppiti; Madhura A Tamhankar; Franz Fogt; Malena Amato; Edward Wood; Vikram Durairaj; Steve Rasmussen; Vigdis Petursdottir; Lea Pollak; Sonia Mendlovic; Denis Chatelain; Kathy Keyvani; Wolfgang Brueck; Maria A Nagel
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

5.  Multifocal VZV vasculopathy with temporal artery infection mimics giant cell arteritis.

Authors:  Maria A Nagel; Jeffrey L Bennett; Nelly Khmeleva; Alexander Choe; April Rempel; Philip J Boyer; Don Gilden
Journal:  Neurology       Date:  2013-05-01       Impact factor: 9.910

6.  Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis.

Authors:  Maria A Nagel; Teresa White; Nelly Khmeleva; April Rempel; Philip J Boyer; Jeffrey L Bennett; Andrea Haller; Kelly Lear-Kaul; Balasurbramaniyam Kandasmy; Malena Amato; Edward Wood; Vikram Durairaj; Franz Fogt; Madhura A Tamhankar; Hans E Grossniklaus; Robert J Poppiti; Brian Bockelman; Kathy Keyvani; Lea Pollak; Sonia Mendlovic; Mary Fowkes; Charles G Eberhart; Mathias Buttmann; Klaus V Toyka; Tobias Meyer-ter-Vehn; Vigdis Petursdottir; Don Gilden
Journal:  JAMA Neurol       Date:  2015-11       Impact factor: 18.302

  6 in total
  15 in total

1.  Severe Post-Herpetic Lumbar Plexopathy Responds to Pulse Intravenous Methylprednisolone: A Case Report With a Side Note on its Parallel Semiology to Diabetic Radiculoplexopathy and the Vascular Invasiveness of the Varicella-Zoster Virus.

Authors:  Hassan Kesserwani
Journal:  Cureus       Date:  2020-12-19

Review 2.  Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis.

Authors:  Maria A Nagel; Dallas Jones; Ann Wyborny
Journal:  J Neuroimmunol       Date:  2017-03-18       Impact factor: 3.478

3.  Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons.

Authors:  Christina N Como; Catherine M Pearce; Randall J Cohrs; Nicholas L Baird
Journal:  Virology       Date:  2018-07-04       Impact factor: 3.616

4.  Targeted Genome Sequencing Reveals Varicella-Zoster Virus Open Reading Frame 12 Deletion.

Authors:  Randall J Cohrs; Katherine S Lee; Addilynn Beach; Bridget Sanford; Nicholas L Baird; Christina Como; Chiharu Graybill; Dallas Jones; Eden Tekeste; Mitchell Ballard; Xiaomi Chen; David Yalacki; Seth Frietze; Kenneth Jones; Tihana Lenac Rovis; Stipan Jonjić; Jürgen Haas; Don Gilden
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 5.  Varicella Zoster Virus in Giant Cell Arteritis: A Review of Current Medical Literature.

Authors:  Rochella A Ostrowski; Sheela Metgud; Rodney Tehrani; Walter M Jay
Journal:  Neuroophthalmology       Date:  2019-07-02

6.  Varicella Zoster Virus Alters Expression of Cell Adhesion Proteins in Human Perineurial Cells via Interleukin 6.

Authors:  Anna M Blackmon; Christina N Como; Andrew N Bubak; Teresa Mescher; Dallas Jones; Maria A Nagel
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

Review 7.  Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.

Authors:  Catherine Amlie-Lefond; Don Gilden
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-04-29       Impact factor: 2.136

Review 8.  Varicella zoster virus triggers the immunopathology of giant cell arteritis.

Authors:  Don Gilden; Maria A Nagel
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

9.  Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Andrew N Bubak
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

10.  Alphabet soup.

Authors:  Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.